# Jazz Pharmaceuticals

销售Epidiolex，一款经FDA批准的植物来源CBD药物，用于治疗严重儿童癫痫；该产品2026年第一季度销售额同比增长15%，同期公司整体营收增长19%。

Source: https://cn.bioecon.ru/companies/jazz-pharmaceuticals/
Updated: 2026-07-03

- 国家: Ireland
- 代码: JAZZ

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 营收 | 2026年第一季度Epidiolex/Epidyolex产品净销售额$2.5亿，同比增长15% | https://finance.yahoo.com/sectors/healthcare/articles/jazz-pharmaceuticals-plc-jazz-cbd-121554621.html, https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-first-quarter-2026-financial, https://www.sec.gov/Archives/edgar/data/1232524/000123252426000024/a1q26financialpr.htm |
| 营收 | 2026年第一季度总收入$11亿，同比增长19% | https://finance.yahoo.com/sectors/healthcare/articles/jazz-pharmaceuticals-plc-jazz-cbd-121554621.html, https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-first-quarter-2026-financial, https://www.sec.gov/Archives/edgar/data/1232524/000123252426000024/a1q26financialpr.htm |
| 营收 | 2026年第二季度Epidiolex/Epidyolex净产品销售额为$2.921亿,同比增长16% | https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-second-quarter-2026-financial |
| 营收 | 2026年第二季度总营收$1.2083 billion | https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-second-quarter-2026-financial |
| 生产基地 | 位于爱尔兰阿斯隆的生产研发设施；位于英国肯特科学园的生产设施；位于意大利维拉瓜迪亚的生产工厂 | http://www.jazzpharma.com/sites/jazzpharmaceuticals/files/2026-06/2025_Jazz_Pharmaceuticals_CSSI_Report_F.pdf, https://www.jazzpharma.com/medicines/manufacturing |
| 监管批准 | 获 FDA 批准用于治疗1岁及以上患者的 LGS、DS 和 TSC 相关癫痫发作；也在欧洲、英国、加拿大、以色列、澳大利亚、瑞士、台湾和新西兰等国际市场获批 | https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-present-research-epidiolexr-cannabidiol-and, https://www.epidiolex.com/, https://www.marketscreener.com/news/jazz-pharmaceuticals-quarterly-report-for-quarter-ending-march-31-2026-form-10-q-ce7f58ddd88ef025 |
| 认证 | 内部生产厂区均通过ISO 45001及ISO 14001:2015标准认证 | http://www.jazzpharma.com/sites/jazzpharmaceuticals/files/2026-06/2025_Jazz_Pharmaceuticals_CSSI_Report_F.pdf |

独立来源: epidiolex.com, finance.yahoo.com, investor.jazzpharma.com, marketscreener.com, sec.gov

## 技术

- [生物合成大麻素（CBD 与 THC）](https://cn.bioecon.ru/technology/biosynthetic-cannabinoids-cbd-thc/)